Second MCL Complete Response in BTKi Trial

Imugene Ltd has announced a significant development from its ongoing Phase 1b azer-cel trial, marking a second complete response within the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort. This achievement bolsters early clinical findings in a patient group with limited treatment alternatives. The latest positive result was documented in the first mantle cell lymphoma (MCL) patient enrolled in the study. This patient had previously undergone BTKi therapy without success but subsequently achieved a complete response, confirmed at the Day 28 evaluation.

This milestone is especially noteworthy given the aggressive nature of MCL. While BTKi therapies can be effective for extended periods, patients who progress or cease responding often experience rapid health deterioration. Clinicians confirmed a complete response, characterized by the absence of tumor markers and total tumor shrinkage, at an earlier stage than anticipated. This development follows Imugene's initial complete response in the same patient group, highlighting a pattern of early success in patients who have relapsed or are refractory to BTKi treatments.

The company is exploring business development opportunities, recognizing BTKi therapies as a major drug class. Azer-cel's design targets the reasons why these therapies may cease to be effective for certain individuals. The objective is to enable patients to continue their existing treatments by restoring therapeutic efficacy. Imugene is in active discussions with pharmaceutical companies, with some collaborations progressing more rapidly than others.

Looking forward, Imugene is concurrently administering azer-cel alongside an approved drug. This combination approach could potentially expedite the path toward a registration strategy. The immediate focus, however, remains on advancing discussions with pharmaceutical companies, viewing collaboration and partnership as the natural progression for azer-cel's development.